Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Posted: 23 January Amplia Therapeutics Limited is pleased to advise that following a review of safety data collected to date, the ACCENT clinical trial’s Safety Review Committee has approved dose escalation of AMP945 and recruitment of another patient…
Monash University and Ono Pharmaceutical Announce Collaboration Agreement
Posted: 23 January An Option and Research Collaboration Agreement has been established between Monash University and Japan-based Ono Pharmaceutical Co. Ltd, which brings together extensive expertise in the discovery and development of antibodies targeting G protein-coupled receptors (GPCRs)…
FDA Includes Paediatric Patients in Dimerix Phase 3 FSGS Study
Posted: 13 January Dimerix Limited, a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, confirmed the outcomes of a meeting with the US Food and Drug Administration (FDA) to discuss the paediatric plan for DMX-200 in Focal…
Cartherics granted first patent in China for multiple development candidates
Posted: 9 January 2023 Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This…
Starpharma receives $7.1M research and development tax incentive refund
Posted: 9 January 2023 Starpharma Holdings Limited announces it has received a $7.1M research and development (R&D) tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme. The tax refund relates to Starpharma’s Australian and international…
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Posted: 9 January 2023 Immutep announces the results of a positive follow-up Type C meeting with the US Food and Drug Administration (FDA) regarding late-stage clinical development plans for its first-in-class soluble LAG-3 protein, eftilagimod alpha (“efti”), in…
Cartherics to Present at Biotech Showcase 2023
Posted: 9 January 2023 Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program at Biotech Showcase, with a view to engaging with potential investors and partners Cartherics, a biotechnology company developing immune cell therapies…
Ethics Approval received for Phase III Clinical Trial
Posted: 9 January 2023 Avecho Biotechnology Limited has announced that it has now received ethics approval for our Phase III clinical trial, testing oral CBD softgel capsule for insomnia. Avecho is on track to commence the largest randomised,…
Neuren IND submitted and first patients complete Phase 2 trials
Posted: 9 January 2023 Neuren Pharmaceuticals announced the submission of an Investigational New Drug (IND) application for NNZ-2591 in Prader-Willi syndrome and provided an update on progress in its ongoing Phase 2 clinical trials for each of PhelanMcDermid,…
Collaboration with Leading Canadian Cancer Center Commences with Lecture from Supportive and Palliative Care Expert
Posted: 15 December Peter Mac continues to expand its global cancer network through a formal alliance partnership with one of the world’s leading cancer research centres, Toronto’s Princess Margaret Cancer Centre. Princess Margaret is the largest comprehensive cancer…
Campus Plus, Science and Technology Australia, and Cruxes Innovation to Deliver Industry PHD Program
Posted: 15 December Campus Plus, Science & Technology Australia, and Cruxes Innovation are delighted to have been chosen to deliver the new National Industry PhD program for the Department of Education. The National Industry PhD Program will powerfully…
Breaking ground: Moderna’s big build begins
Posted: 14 December In an important milestone for securing access to mRNA vaccines and enhancing medical research and development in Australia, global biotech Moderna has commenced construction of its new manufacturing facility at Monash University’s Clayton campus in…
